尿検査：市場予測（2022年～2027年）

世界の尿検査の市場規模は、2020年に26億8,900万米ドルとなり、予測期間中に5.82％のCAGRで拡大し、2027年に39億9,600万米ドルになると予測されています。

当レポートでは、尿検査の世界市場を調査し、市場規模や予測、市場の促進要因および課題、市場動向、セグメント別の市場分析、競合情勢、主要企業のプロファイルなどの体系的な情報を提供しています。

目次

第1章 イントロダクション

• 市場概要
• COVID-19のシナリオ　
• 市場の定義

市場セグメンテーション

第2章 調査手法

• 調査データ
• 仮定

第3章 エグゼクティブサマリー

• 調査のハイライト

第4章 市場力学

• 市場促進要因
• 市場抑制要因
• ポーターのファイブフォース分析
  • エンドユーザーの交渉力
  • 買い手の交渉力
  • 新規参入者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• 業界のバリューチェーン分析

第5章 世界の尿検査市場分析：製品タイプ別

• イントロダクション
• 機器
  • 自動尿分析装置
  • 半自動尿分析装置
  • ポイントオブケア尿分析装置
• 消耗品
  • 試薬
  • キット
  • ディップスティック
  • 使い捨て品

第6章 世界の尿検査市場分析：検査タイプ別

• イントロダクション
• 生化学的
• 妊娠およびファティリティー
• 堆積物

第7章 世界の尿検査市場分析：用途別

• イントロダクション
• 尿路感染症
• 糖尿病
• 腎臓病
• 肝疾患
• 妊娠とファティリティー
• その他

第8章 世界の尿検査市場分析：エンドユーザー別

• イントロダクション
• 病院と診療所
• 診断研究所
• 調査機関および学術機関
• 在宅医療

第9章 世界の尿検査市場分析：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ
  • その他
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • 台湾
  • タイ
  • インドネシア
  • その他

第10章 競合環境と分析

• 主要企業と戦略分析
• 新興企業と市場の収益性
• 合併、買収、合意、およびコラボレーション
• ベンダー競争力マトリックス

第11章 企業プロファイル

• ARKRAY, Inc.
• 77 Elektronika Kft.
• Siemens Healthineers AG
• F. Hoffmann-La Roche Ltd.
• Beckman Coulter, Inc.
• Abbott Laboratories
• Sysmex Corporation
• Neomedica d.o.o.
• Mindray Medical International Limited
• Analis sa/nv

The global urinalysis market is expected to grow at a compound annual growth rate of 5.82% over the forecast period to reach a market size of US$3.996 billion in 2027 from US$2.689 billion in 2020.

Urinalysis is a urine test that is used to diagnose and treat a variety of conditions, including urinary tract infections (UTI), kidney disease, and diabetes. During a urinalysis, the appearance, concentration, and content of urine are all evaluated. Abnormal urine findings may indicate a condition or illness. In September 2021, according to Eurek Aert, the Translational Genomics Research Institute (TGen), a City of Hope affiliate, had discovered a method to pinpoint early-stage cancer by utilizing Urinalysis to analyze small strands of cell-free DNA in urine. Various non-invasive urine automated analyzers have been developed to provide rapid and accurate test results.

The increased prevalence of UTIs, diabetes, and kidney and liver disorders, as well as the growing geriatric population and the resulting increase in age-related diseases, are driving market expansion. In hospitals and other critical care units and medical-surgical units, the prevalence of conditions such as UTI, renal disease, and diabetes is likely to be greater. According to the National Centre of Biotechnology Information, one-third of women will have experienced a UTI by the age of 24, and half by the age of 32. According to the International Diabetes Federation, about 463 million individuals, between the age of 20-79 years, had diabetes in 2019, and this number is expected to grow to 700 million by 2045. Furthermore, according to the National Kidney Foundation, chronic kidney disease (CKD) affects 10% of the world's population, with millions dying each year.

However, the market expansion is likely to be hampered in the coming years by a strict regulatory framework and an unfavorable reimbursement condition.

Due to an aging population and a high prevalence of CKD, the North American market is projected to have a significant market position. Kidney failure, high blood pressure, and diabetes are all linked to chronic kidney disease. According to the National Kidney Foundation, each year more people die due to CKD than breast cancer and prostate cancer. In the United States, kidney disease is a major cause of death. It now affects around 37 million individuals in the US. It is more common in the aging population, affecting around 15% of the adult population. Kidney disease affects around one in every three individuals with diabetes and one in every five adults with high blood pressure. Hence, there is a growing demand for accurate detection and treatment of CKD, and these factors are likely to drive up demand for urinalysis.

Growth Factors

Rising geriatric population and age-related diseases.

The growing geriatric population in developed and developing countries will boost the urinalysis market growth. According to the World Health Organization, the number of adults aged 60 and more will surpass children under the age of five by 2020. The prevalence of age-related diseases such as diabetes, kidney and liver disease is projected to rise dramatically as the geriatric population grows. According to the International Diabetes Organization, one in every five persons over the age of 65 has diabetes. Prescriptions for tests such as creatinine, albumin, glucose, ketones, and bilirubin, among others, are on the rise as a result of the increased diagnosis and treatment of such disorders, which is benefiting urinalysis, which is used to perform these tests.

Restraints

• Unfavorable reimbursement conditions

The availability of refurbished instruments, which provide the same functionality as new equipment at a cheaper cost, poses a barrier to market growth. A number of end customers, primarily small and medium-sized laboratories, choose cost-effective reconditioned equipment. Particularly in developing nations, where markets are price-sensitive, inexpensive instruments with equivalent functions are preferred. This is likely to limit the revenue of companies who sell branded analyzers, thus limiting the market growth.

Impact of COVID-19 on the urinalysis market

The COVID-19 outbreak had a detrimental impact on the total revenue of many market players. Lockdowns imposed due to the pandemic prompted patients to postpone or delay their health checkups, thus reducing the number of tests conducted and reagent sales. However, as governments increasingly loosen restrictions, there is a rise in testing numbers. Furthermore, COVID-19 is more likely to target individuals with kidney disease, kidney transplant patients, and those at risk for kidney disease, according to the National Kidney Foundation.

Competitive Insight:

• October 2021 - Olive Diagnostics, a home-based Urinalysis technology developer, began a funding round supported by the Maccabi Foundation for the world's first hands-free toilet optical sensor targeting early disease detection in the elderly and pregnant women
• September 2021 - At the AACC Annual Scientific Meeting & Clinical Lab Expo, Beckman Coulter unveiled DxU Iris Workcell, a revolutionary urinalysis solution that reduces sample processing time.
• June 2020 - Healthy.io, an Israeli smartphone urinalysis and wound-care startup spent $9 million in cash to acquire fellow home-diagnostics company Inui Health.

Market Segmentation:

• By Product Type

Instruments

• Automated Urine Analyzer
• Semi-automated Urine Analyzer
• Point-of-Care Urine Analyzer

Consumables

• Reagents
• Kits
• Dipsticks
• Disposables
• By Test Type

Biochemical Urinalysis

Pregnancy & Fertility Urinalysis

Sediment Urinalysis

• By Application

Urinary Tract Infections

Diabetes

Kidney Diseases

Liver Diseases

Pregnancy and Fertility

Others

• By End-User

Hospitals & Clinics

Diagnostic Laboratories

Research & Academic Institutions

Home Care Settings

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• Germany
• France
• UK
• Italy
• Spain
• Others

Middle East and Africa

• Saudi Arabia
• UAE
• South Africa
• Others

Asia Pacific

• China
• India
• Japan
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Overview
• 1.2. Covid-19 Scenaro
• 1.3. Market Defnition

1.4. Market Segmentation

2. Research Methodology

• 2.1. Research Data
• 2.2. Assumptions

3. Executive Summary

• 3.1. Research Highlights

4. Market Dynamics

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of End-Users
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. Global Urinalysis Market Analysis, by Product Type

• 5.1. Introduction
• 5.2. Instruments
  • 5.2.1. Automated Urine Analyzer
  • 5.2.2. Semi-automated Urine Analyzer
  • 5.2.3. Point-of-Care Urine Analyzer
• 5.3. Consumables
  • 5.3.1. Reagents
  • 5.3.2. Kits
  • 5.3.3. Dipsticks
  • 5.3.4. Disposables

6. Global Urinalysis Market Analysis, by Test Type

• 6.1. Introduction
• 6.2. Biochemical Urinalysis
• 6.3. Pregnancy & Fertility Urinalysis
• 6.4. Sediment Urinalysis

7. Global Urinalysis Market Analysis, by Application

• 7.1. Introduction
• 7.2. Urinary Tract Infections
• 7.3. Diabetes
• 7.4. Kidney Diseases
• 7.5. Liver Diseases
• 7.6. Pregnancy and Fertility
• 7.7. Others

8. Global Urinalysis Market Analysis, by End-User

• 8.1. Introduction
• 8.2. Hospitals & Clinics
• 8.3. Diagnostic Laboratories
• 8.4. Research & Academic Institutions
• 8.5. Home Care Settings

9. Global Urinalysis Market Analysis, by Geography

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. USA
  • 9.2.2. Canada
  • 9.2.3. Mexico
• 9.3. South America
  • 9.3.1. Brazil
  • 9.3.2. Argentina
  • 9.3.3. Others
• 9.4. Europe
  • 9.4.1. Germany
  • 9.4.2. France
  • 9.4.3. UK
  • 9.4.4. Italy
  • 9.4.5. Spain
  • 9.4.6. Others
• 9.5. Middle East and Africa
  • 9.5.1. Saudi Arabia
  • 9.5.2. UAE
  • 9.5.3. South Africa
  • 9.5.4. Others
• 9.6. Asia Pacific
  • 9.6.1. China
  • 9.6.2. India
  • 9.6.3. Japan
  • 9.6.4. South Korea
  • 9.6.5. Taiwan
  • 9.6.6. Thailand
  • 9.6.7. Indonesia
  • 9.6.8. Others

10. Competitive Environment and Analysis

• 10.1. Major Players and Strategy Analysis
• 10.2. Emerging Players and Market Lucrativenessness
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Vendor Competitiveness Matrix

11. Company Profiles 

• 11.1. ARKRAY, Inc.
• 11.2. 77 Elektronika Kft.
• 11.3. Siemens Healthineers AG
• 11.4. F. Hoffmann-La Roche Ltd.
• 11.5. Beckman Coulter, Inc.
• 11.6. Abbott Laboratories
• 11.7. Sysmex Corporation
• 11.8. Neomedica d.o.o.
• 11.9. Mindray Medical International Limited
• 11.10. Analis sa/nv